APO RESEARCH · REPORT
Latisse (Bimatoprost)
Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Product & engineering
Understand the product.
Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Selected research
Market Structure
Global Latisse (Bimatoprost) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Global Latisse (Bimatoprost) (CAS 155206-00-1) key players include Chirogate International, Cayman Pharma, Zhejiang Ausun, Everlight Chemical, and Lianmin Biochemical etc. Global top three players hold a share about 40%. North America is the largest market, with a share about 90%.
This report provides an overview of the global Latisse (Bimatoprost) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Latisse (Bimatoprost) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Latisse (Bimatoprost) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Latisse (Bimatoprost) market size, projected growth trends, production technologies, key applications, and end-use industries.
Latisse (Bimatoprost) Segment by Company
Cayman Pharma
Tecoland Corporation
TCS Group
Changzhou BOHIV
Zhejiang Ausun
Ansion Pharma
Lianmin Biochemical
Chirogate International
Everlight Chemical
GENTEC
Latisse (Bimatoprost) Segment by Purity
Below 99.5%
Other
Latisse (Bimatoprost) Segment by Application
Patented Product
General Products
Latisse (Bimatoprost) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Latisse (Bimatoprost) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Latisse (Bimatoprost) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Latisse (Bimatoprost).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Latisse (Bimatoprost) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Latisse (Bimatoprost) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Latisse (Bimatoprost) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Latisse (Bimatoprost) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Below 99.5%
- Other
Applications
- Patented Product
- General Products
Companies covered
- Cayman Pharma
- Tecoland Corporation
- TCS Group
- Changzhou BOHIV
- Zhejiang Ausun
- Ansion Pharma
- Lianmin Biochemical
- Chirogate International
- Everlight Chemical
- GENTEC
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Latisse (Bimatoprost) Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Latisse (Bimatoprost) Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Latisse (Bimatoprost) Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Latisse (Bimatoprost) Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Latisse (Bimatoprost) Market Dynamics
- 2.1 Latisse (Bimatoprost) Industry Trends
- 2.2 Latisse (Bimatoprost) Industry Drivers
- 2.3 Latisse (Bimatoprost) Industry Opportunities and Challenges
- 2.4 Latisse (Bimatoprost) Industry Restraints
3 Latisse (Bimatoprost) Market by Manufacturers
- 3.1 Global Latisse (Bimatoprost) Revenue by Manufacturers (2021-2026)
- 3.2 Global Latisse (Bimatoprost) Sales by Manufacturers (2021-2026)
- 3.3 Global Latisse (Bimatoprost) Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Latisse (Bimatoprost) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Latisse (Bimatoprost) Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Latisse (Bimatoprost) Manufacturers, Product Type & Application
- 3.7 Global Latisse (Bimatoprost) Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Latisse (Bimatoprost) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Latisse (Bimatoprost) Players Market Share by Revenue in 2025
- 3.8.3 2025 Latisse (Bimatoprost) Tier 1, Tier 2, and Tier 3
4 Latisse (Bimatoprost) Market by Type
- 4.1 Latisse (Bimatoprost) Type Introduction
- 4.1.1 Below 99.5%
- 4.1.2 Other
- 4.2 Global Latisse (Bimatoprost) Sales by Type
- 4.2.1 Global Latisse (Bimatoprost) Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Latisse (Bimatoprost) Sales by Type (2021-2032)
- 4.2.3 Global Latisse (Bimatoprost) Sales Market Share by Type (2021-2032)
- 4.3 Global Latisse (Bimatoprost) Revenue by Type
- 4.3.1 Global Latisse (Bimatoprost) Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Latisse (Bimatoprost) Revenue by Type (2021-2032)
- 4.3.3 Global Latisse (Bimatoprost) Revenue Market Share by Type (2021-2032)
5 Latisse (Bimatoprost) Market by Application
- 5.1 Latisse (Bimatoprost) Application Introduction
- 5.1.1 Patented Product
- 5.1.2 General Products
- 5.2 Global Latisse (Bimatoprost) Sales by Application
- 5.2.1 Global Latisse (Bimatoprost) Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Latisse (Bimatoprost) Sales by Application (2021-2032)
- 5.2.3 Global Latisse (Bimatoprost) Sales Market Share by Application (2021-2032)
- 5.3 Global Latisse (Bimatoprost) Revenue by Application
- 5.3.1 Global Latisse (Bimatoprost) Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Latisse (Bimatoprost) Revenue by Application (2021-2032)
- 5.3.3 Global Latisse (Bimatoprost) Revenue Market Share by Application (2021-2032)
6 Global Latisse (Bimatoprost) Sales by Region
- 6.1 Global Latisse (Bimatoprost) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Latisse (Bimatoprost) Sales by Region (2021-2032)
- 6.2.1 Global Latisse (Bimatoprost) Sales by Region (2021-2026)
- 6.2.2 Global Latisse (Bimatoprost) Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Latisse (Bimatoprost) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Latisse (Bimatoprost) Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Latisse (Bimatoprost) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Latisse (Bimatoprost) Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Latisse (Bimatoprost) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Latisse (Bimatoprost) Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Latisse (Bimatoprost) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Latisse (Bimatoprost) Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Latisse (Bimatoprost) Revenue by Region
- 7.1 Global Latisse (Bimatoprost) Revenue by Region
- 7.1.1 Global Latisse (Bimatoprost) Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Latisse (Bimatoprost) Revenue by Region (2021-2026)
- 7.1.3 Global Latisse (Bimatoprost) Revenue by Region (2027-2032)
- 7.1.4 Global Latisse (Bimatoprost) Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Latisse (Bimatoprost) Revenue (2021-2032)
- 7.2.2 North America Latisse (Bimatoprost) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Latisse (Bimatoprost) Revenue (2021-2032)
- 7.3.2 Europe Latisse (Bimatoprost) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Latisse (Bimatoprost) Revenue (2021-2032)
- 7.4.2 Asia-Pacific Latisse (Bimatoprost) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Latisse (Bimatoprost) Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Latisse (Bimatoprost) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Cayman Pharma
- 8.1.1 Cayman Pharma Company Information
- 8.1.2 Cayman Pharma Business Overview
- 8.1.3 Cayman Pharma Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Cayman Pharma Latisse (Bimatoprost) Product Portfolio
- 8.1.5 Cayman Pharma Recent Developments
- 8.2 Tecoland Corporation
- 8.2.1 Tecoland Corporation Company Information
- 8.2.2 Tecoland Corporation Business Overview
- 8.2.3 Tecoland Corporation Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Tecoland Corporation Latisse (Bimatoprost) Product Portfolio
- 8.2.5 Tecoland Corporation Recent Developments
- 8.3 TCS Group
- 8.3.1 TCS Group Company Information
- 8.3.2 TCS Group Business Overview
- 8.3.3 TCS Group Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 TCS Group Latisse (Bimatoprost) Product Portfolio
- 8.3.5 TCS Group Recent Developments
- 8.4 Changzhou BOHIV
- 8.4.1 Changzhou BOHIV Company Information
- 8.4.2 Changzhou BOHIV Business Overview
- 8.4.3 Changzhou BOHIV Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Changzhou BOHIV Latisse (Bimatoprost) Product Portfolio
- 8.4.5 Changzhou BOHIV Recent Developments
- 8.5 Zhejiang Ausun
- 8.5.1 Zhejiang Ausun Company Information
- 8.5.2 Zhejiang Ausun Business Overview
- 8.5.3 Zhejiang Ausun Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Zhejiang Ausun Latisse (Bimatoprost) Product Portfolio
- 8.5.5 Zhejiang Ausun Recent Developments
- 8.6 Ansion Pharma
- 8.6.1 Ansion Pharma Company Information
- 8.6.2 Ansion Pharma Business Overview
- 8.6.3 Ansion Pharma Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Ansion Pharma Latisse (Bimatoprost) Product Portfolio
- 8.6.5 Ansion Pharma Recent Developments
- 8.7 Lianmin Biochemical
- 8.7.1 Lianmin Biochemical Company Information
- 8.7.2 Lianmin Biochemical Business Overview
- 8.7.3 Lianmin Biochemical Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Lianmin Biochemical Latisse (Bimatoprost) Product Portfolio
- 8.7.5 Lianmin Biochemical Recent Developments
- 8.8 Chirogate International
- 8.8.1 Chirogate International Company Information
- 8.8.2 Chirogate International Business Overview
- 8.8.3 Chirogate International Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Chirogate International Latisse (Bimatoprost) Product Portfolio
- 8.8.5 Chirogate International Recent Developments
- 8.9 Everlight Chemical
- 8.9.1 Everlight Chemical Company Information
- 8.9.2 Everlight Chemical Business Overview
- 8.9.3 Everlight Chemical Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Everlight Chemical Latisse (Bimatoprost) Product Portfolio
- 8.9.5 Everlight Chemical Recent Developments
- 8.10 GENTEC
- 8.10.1 GENTEC Company Information
- 8.10.2 GENTEC Business Overview
- 8.10.3 GENTEC Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 GENTEC Latisse (Bimatoprost) Product Portfolio
- 8.10.5 GENTEC Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Latisse (Bimatoprost) Value Chain Analysis
- 9.1.1 Latisse (Bimatoprost) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Latisse (Bimatoprost) Production Mode & Process
- 9.2 Latisse (Bimatoprost) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Latisse (Bimatoprost) Distributors
- 9.2.3 Latisse (Bimatoprost) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst